long-term effects of glp-1 receptor agonists Potential Use and GIP/GLP-1 for Respiratory Disorders: Where Are We at? The cardiovascular effects of GLP-1

Among non-elderly adults with ESI (estimated to be 116.8 million from NHIS), 42%, or 49.3 million people, are clinically eligible for GLP-1 drugs

Large cardiovascular trials and pooled analyses have not shown a statistically higher pancreatitis incidence than placebo beyond what is expected in diabetics (who inherently have some risk)

When intestinal lipopolysaccharide (LPS) causes metabolic syndrome, the individuals microbiota metabolites and AhR activity are impaired

Plateaued results: Some people lose weight at first but hit a plateau, leaving them looking for stronger options

NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production

QTc interval corrected Q wave / T wave interval